Verily is closing its medical device program as Alphabet shifts more resources to AI

In a bold move reflective of Alphabet's strategic realignment, Verily, the life sciences division, has announced the closure of its medical device program, leading to significant staff layoffs. CEO Stephen Gillett communicated this challenging decision to employees through an internal memo, as reported by Business Insider. Gillett emphasized the legacy that Verily has created in the realm of innovative medical devices, but acknowledged that the company's future direction necessitates tough choices. As Verily pivots its focus toward artificial intelligence and enhancing data infrastructure, the decision marks a pivotal moment in its evolution. This shift aligns with Alphabet's broader strategy to channel resources into AI development while streamlining operations. Over recent years, the tech giant has initiated several layoffs, including reductions in its HR and cloud sectors earlier this year. In the spring, the company also offered voluntary exit programs to its extensive workforce of over 25,000 in the Platforms & Devices division. The most significant job cuts took place in January 2023, when Alphabet eliminated 12,000 positions—approximately 6% of its total workforce—amid predictions of an economic downturn. This shake-up in workforce coincided with the explosive growth of ChatGPT, which became the fastest-growing consumer software application, rapidly amassing over 100 million users in just two months. This phenomenon sparked a generative AI boom, reshaping the tech industry's focus and priorities.